A phase II trial of paclitaxel, carboplatin, and bevacizumab in advanced and recurrent endometrial carcinoma (EMCA)
To evaluate the effect of adding bevacizumab to adjuvant paclitaxel and carboplatin and as maintenance on progression-free survival (PFS) in advanced or recurrent endometrial carcinoma (EMCA).
Gespeichert in:
| Autor*in: |
Simpkins, Fiona [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2015 |
|---|
| Umfang: |
6 |
|---|
| Übergeordnetes Werk: |
Enthalten in: Frequency and predictors of missed visits to primary care and eye care providers for annually recommended diabetes preventive care services over a two-year period among U.S. adults with diabetes - Gibson, Diane M. ELSEVIER, 2017, an international journal : official publication of the Society of Gynecologic Oncologists [u.a.], Orlando, Fla |
|---|---|
| Übergeordnetes Werk: |
volume:136 ; year:2015 ; number:2 ; pages:240-245 ; extent:6 |
| Links: |
|---|
| DOI / URN: |
10.1016/j.ygyno.2014.12.004 |
|---|
| Katalog-ID: |
ELV012713724 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | ELV012713724 | ||
| 003 | DE-627 | ||
| 005 | 20230623101506.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 180602s2015 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ygyno.2014.12.004 |2 doi | |
| 028 | 5 | 2 | |a GBVA2015001000028.pica |
| 035 | |a (DE-627)ELV012713724 | ||
| 035 | |a (ELSEVIER)S0090-8258(14)01559-5 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | |a 610 | |
| 082 | 0 | 4 | |a 610 |q DE-600 |
| 082 | 0 | 4 | |a 610 |q VZ |
| 084 | |a 44.11 |2 bkl | ||
| 100 | 1 | |a Simpkins, Fiona |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a A phase II trial of paclitaxel, carboplatin, and bevacizumab in advanced and recurrent endometrial carcinoma (EMCA) |
| 264 | 1 | |c 2015 | |
| 300 | |a 6 | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a To evaluate the effect of adding bevacizumab to adjuvant paclitaxel and carboplatin and as maintenance on progression-free survival (PFS) in advanced or recurrent endometrial carcinoma (EMCA). | ||
| 700 | 1 | |a Drake, Richard |4 oth | |
| 700 | 1 | |a Escobar, Pedro F. |4 oth | |
| 700 | 1 | |a Nutter, Benjamin |4 oth | |
| 700 | 1 | |a Rasool, Nabila |4 oth | |
| 700 | 1 | |a Rose, Peter G. |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |n Academic Press |a Gibson, Diane M. ELSEVIER |t Frequency and predictors of missed visits to primary care and eye care providers for annually recommended diabetes preventive care services over a two-year period among U.S. adults with diabetes |d 2017 |d an international journal : official publication of the Society of Gynecologic Oncologists [u.a.] |g Orlando, Fla |w (DE-627)ELV000708127 |
| 773 | 1 | 8 | |g volume:136 |g year:2015 |g number:2 |g pages:240-245 |g extent:6 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.ygyno.2014.12.004 |3 Volltext |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a GBV_ELV | ||
| 912 | |a SYSFLAG_U | ||
| 912 | |a SSG-OLC-PHA | ||
| 936 | b | k | |a 44.11 |j Präventivmedizin |q VZ |
| 951 | |a AR | ||
| 952 | |d 136 |j 2015 |e 2 |h 240-245 |g 6 | ||
| 953 | |2 045F |a 610 | ||
| author_variant |
f s fs |
|---|---|
| matchkey_str |
simpkinsfionadrakerichardescobarpedrofnu:2015----:paeiraopciaecroltnnbvczmbndacdnrcret |
| hierarchy_sort_str |
2015 |
| bklnumber |
44.11 |
| publishDate |
2015 |
| allfields |
10.1016/j.ygyno.2014.12.004 doi GBVA2015001000028.pica (DE-627)ELV012713724 (ELSEVIER)S0090-8258(14)01559-5 DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ 44.11 bkl Simpkins, Fiona verfasserin aut A phase II trial of paclitaxel, carboplatin, and bevacizumab in advanced and recurrent endometrial carcinoma (EMCA) 2015 6 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier To evaluate the effect of adding bevacizumab to adjuvant paclitaxel and carboplatin and as maintenance on progression-free survival (PFS) in advanced or recurrent endometrial carcinoma (EMCA). Drake, Richard oth Escobar, Pedro F. oth Nutter, Benjamin oth Rasool, Nabila oth Rose, Peter G. oth Enthalten in Academic Press Gibson, Diane M. ELSEVIER Frequency and predictors of missed visits to primary care and eye care providers for annually recommended diabetes preventive care services over a two-year period among U.S. adults with diabetes 2017 an international journal : official publication of the Society of Gynecologic Oncologists [u.a.] Orlando, Fla (DE-627)ELV000708127 volume:136 year:2015 number:2 pages:240-245 extent:6 https://doi.org/10.1016/j.ygyno.2014.12.004 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 44.11 Präventivmedizin VZ AR 136 2015 2 240-245 6 045F 610 |
| spelling |
10.1016/j.ygyno.2014.12.004 doi GBVA2015001000028.pica (DE-627)ELV012713724 (ELSEVIER)S0090-8258(14)01559-5 DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ 44.11 bkl Simpkins, Fiona verfasserin aut A phase II trial of paclitaxel, carboplatin, and bevacizumab in advanced and recurrent endometrial carcinoma (EMCA) 2015 6 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier To evaluate the effect of adding bevacizumab to adjuvant paclitaxel and carboplatin and as maintenance on progression-free survival (PFS) in advanced or recurrent endometrial carcinoma (EMCA). Drake, Richard oth Escobar, Pedro F. oth Nutter, Benjamin oth Rasool, Nabila oth Rose, Peter G. oth Enthalten in Academic Press Gibson, Diane M. ELSEVIER Frequency and predictors of missed visits to primary care and eye care providers for annually recommended diabetes preventive care services over a two-year period among U.S. adults with diabetes 2017 an international journal : official publication of the Society of Gynecologic Oncologists [u.a.] Orlando, Fla (DE-627)ELV000708127 volume:136 year:2015 number:2 pages:240-245 extent:6 https://doi.org/10.1016/j.ygyno.2014.12.004 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 44.11 Präventivmedizin VZ AR 136 2015 2 240-245 6 045F 610 |
| allfields_unstemmed |
10.1016/j.ygyno.2014.12.004 doi GBVA2015001000028.pica (DE-627)ELV012713724 (ELSEVIER)S0090-8258(14)01559-5 DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ 44.11 bkl Simpkins, Fiona verfasserin aut A phase II trial of paclitaxel, carboplatin, and bevacizumab in advanced and recurrent endometrial carcinoma (EMCA) 2015 6 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier To evaluate the effect of adding bevacizumab to adjuvant paclitaxel and carboplatin and as maintenance on progression-free survival (PFS) in advanced or recurrent endometrial carcinoma (EMCA). Drake, Richard oth Escobar, Pedro F. oth Nutter, Benjamin oth Rasool, Nabila oth Rose, Peter G. oth Enthalten in Academic Press Gibson, Diane M. ELSEVIER Frequency and predictors of missed visits to primary care and eye care providers for annually recommended diabetes preventive care services over a two-year period among U.S. adults with diabetes 2017 an international journal : official publication of the Society of Gynecologic Oncologists [u.a.] Orlando, Fla (DE-627)ELV000708127 volume:136 year:2015 number:2 pages:240-245 extent:6 https://doi.org/10.1016/j.ygyno.2014.12.004 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 44.11 Präventivmedizin VZ AR 136 2015 2 240-245 6 045F 610 |
| allfieldsGer |
10.1016/j.ygyno.2014.12.004 doi GBVA2015001000028.pica (DE-627)ELV012713724 (ELSEVIER)S0090-8258(14)01559-5 DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ 44.11 bkl Simpkins, Fiona verfasserin aut A phase II trial of paclitaxel, carboplatin, and bevacizumab in advanced and recurrent endometrial carcinoma (EMCA) 2015 6 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier To evaluate the effect of adding bevacizumab to adjuvant paclitaxel and carboplatin and as maintenance on progression-free survival (PFS) in advanced or recurrent endometrial carcinoma (EMCA). Drake, Richard oth Escobar, Pedro F. oth Nutter, Benjamin oth Rasool, Nabila oth Rose, Peter G. oth Enthalten in Academic Press Gibson, Diane M. ELSEVIER Frequency and predictors of missed visits to primary care and eye care providers for annually recommended diabetes preventive care services over a two-year period among U.S. adults with diabetes 2017 an international journal : official publication of the Society of Gynecologic Oncologists [u.a.] Orlando, Fla (DE-627)ELV000708127 volume:136 year:2015 number:2 pages:240-245 extent:6 https://doi.org/10.1016/j.ygyno.2014.12.004 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 44.11 Präventivmedizin VZ AR 136 2015 2 240-245 6 045F 610 |
| allfieldsSound |
10.1016/j.ygyno.2014.12.004 doi GBVA2015001000028.pica (DE-627)ELV012713724 (ELSEVIER)S0090-8258(14)01559-5 DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ 44.11 bkl Simpkins, Fiona verfasserin aut A phase II trial of paclitaxel, carboplatin, and bevacizumab in advanced and recurrent endometrial carcinoma (EMCA) 2015 6 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier To evaluate the effect of adding bevacizumab to adjuvant paclitaxel and carboplatin and as maintenance on progression-free survival (PFS) in advanced or recurrent endometrial carcinoma (EMCA). Drake, Richard oth Escobar, Pedro F. oth Nutter, Benjamin oth Rasool, Nabila oth Rose, Peter G. oth Enthalten in Academic Press Gibson, Diane M. ELSEVIER Frequency and predictors of missed visits to primary care and eye care providers for annually recommended diabetes preventive care services over a two-year period among U.S. adults with diabetes 2017 an international journal : official publication of the Society of Gynecologic Oncologists [u.a.] Orlando, Fla (DE-627)ELV000708127 volume:136 year:2015 number:2 pages:240-245 extent:6 https://doi.org/10.1016/j.ygyno.2014.12.004 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 44.11 Präventivmedizin VZ AR 136 2015 2 240-245 6 045F 610 |
| language |
English |
| source |
Enthalten in Frequency and predictors of missed visits to primary care and eye care providers for annually recommended diabetes preventive care services over a two-year period among U.S. adults with diabetes Orlando, Fla volume:136 year:2015 number:2 pages:240-245 extent:6 |
| sourceStr |
Enthalten in Frequency and predictors of missed visits to primary care and eye care providers for annually recommended diabetes preventive care services over a two-year period among U.S. adults with diabetes Orlando, Fla volume:136 year:2015 number:2 pages:240-245 extent:6 |
| format_phy_str_mv |
Article |
| bklname |
Präventivmedizin |
| institution |
findex.gbv.de |
| dewey-raw |
610 |
| isfreeaccess_bool |
false |
| container_title |
Frequency and predictors of missed visits to primary care and eye care providers for annually recommended diabetes preventive care services over a two-year period among U.S. adults with diabetes |
| authorswithroles_txt_mv |
Simpkins, Fiona @@aut@@ Drake, Richard @@oth@@ Escobar, Pedro F. @@oth@@ Nutter, Benjamin @@oth@@ Rasool, Nabila @@oth@@ Rose, Peter G. @@oth@@ |
| publishDateDaySort_date |
2015-01-01T00:00:00Z |
| hierarchy_top_id |
ELV000708127 |
| dewey-sort |
3610 |
| id |
ELV012713724 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV012713724</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230623101506.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180602s2015 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.ygyno.2014.12.004</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBVA2015001000028.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV012713724</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0090-8258(14)01559-5</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.11</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Simpkins, Fiona</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">A phase II trial of paclitaxel, carboplatin, and bevacizumab in advanced and recurrent endometrial carcinoma (EMCA)</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2015</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">6</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">To evaluate the effect of adding bevacizumab to adjuvant paclitaxel and carboplatin and as maintenance on progression-free survival (PFS) in advanced or recurrent endometrial carcinoma (EMCA).</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Drake, Richard</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Escobar, Pedro F.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Nutter, Benjamin</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Rasool, Nabila</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Rose, Peter G.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Academic Press</subfield><subfield code="a">Gibson, Diane M. ELSEVIER</subfield><subfield code="t">Frequency and predictors of missed visits to primary care and eye care providers for annually recommended diabetes preventive care services over a two-year period among U.S. adults with diabetes</subfield><subfield code="d">2017</subfield><subfield code="d">an international journal : official publication of the Society of Gynecologic Oncologists [u.a.]</subfield><subfield code="g">Orlando, Fla</subfield><subfield code="w">(DE-627)ELV000708127</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:136</subfield><subfield code="g">year:2015</subfield><subfield code="g">number:2</subfield><subfield code="g">pages:240-245</subfield><subfield code="g">extent:6</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.ygyno.2014.12.004</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.11</subfield><subfield code="j">Präventivmedizin</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">136</subfield><subfield code="j">2015</subfield><subfield code="e">2</subfield><subfield code="h">240-245</subfield><subfield code="g">6</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">610</subfield></datafield></record></collection>
|
| author |
Simpkins, Fiona |
| spellingShingle |
Simpkins, Fiona ddc 610 bkl 44.11 A phase II trial of paclitaxel, carboplatin, and bevacizumab in advanced and recurrent endometrial carcinoma (EMCA) |
| authorStr |
Simpkins, Fiona |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)ELV000708127 |
| format |
electronic Article |
| dewey-ones |
610 - Medicine & health |
| delete_txt_mv |
keep |
| author_role |
aut |
| collection |
elsevier |
| remote_str |
true |
| illustrated |
Not Illustrated |
| topic_title |
610 610 DE-600 610 VZ 44.11 bkl A phase II trial of paclitaxel, carboplatin, and bevacizumab in advanced and recurrent endometrial carcinoma (EMCA) |
| topic |
ddc 610 bkl 44.11 |
| topic_unstemmed |
ddc 610 bkl 44.11 |
| topic_browse |
ddc 610 bkl 44.11 |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| author2_variant |
r d rd p f e pf pfe b n bn n r nr p g r pg pgr |
| hierarchy_parent_title |
Frequency and predictors of missed visits to primary care and eye care providers for annually recommended diabetes preventive care services over a two-year period among U.S. adults with diabetes |
| hierarchy_parent_id |
ELV000708127 |
| dewey-tens |
610 - Medicine & health |
| hierarchy_top_title |
Frequency and predictors of missed visits to primary care and eye care providers for annually recommended diabetes preventive care services over a two-year period among U.S. adults with diabetes |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)ELV000708127 |
| title |
A phase II trial of paclitaxel, carboplatin, and bevacizumab in advanced and recurrent endometrial carcinoma (EMCA) |
| ctrlnum |
(DE-627)ELV012713724 (ELSEVIER)S0090-8258(14)01559-5 |
| title_full |
A phase II trial of paclitaxel, carboplatin, and bevacizumab in advanced and recurrent endometrial carcinoma (EMCA) |
| author_sort |
Simpkins, Fiona |
| journal |
Frequency and predictors of missed visits to primary care and eye care providers for annually recommended diabetes preventive care services over a two-year period among U.S. adults with diabetes |
| journalStr |
Frequency and predictors of missed visits to primary care and eye care providers for annually recommended diabetes preventive care services over a two-year period among U.S. adults with diabetes |
| lang_code |
eng |
| isOA_bool |
false |
| dewey-hundreds |
600 - Technology |
| recordtype |
marc |
| publishDateSort |
2015 |
| contenttype_str_mv |
zzz |
| container_start_page |
240 |
| author_browse |
Simpkins, Fiona |
| container_volume |
136 |
| physical |
6 |
| class |
610 610 DE-600 610 VZ 44.11 bkl |
| format_se |
Elektronische Aufsätze |
| author-letter |
Simpkins, Fiona |
| doi_str_mv |
10.1016/j.ygyno.2014.12.004 |
| dewey-full |
610 |
| title_sort |
a phase ii trial of paclitaxel, carboplatin, and bevacizumab in advanced and recurrent endometrial carcinoma (emca) |
| title_auth |
A phase II trial of paclitaxel, carboplatin, and bevacizumab in advanced and recurrent endometrial carcinoma (EMCA) |
| abstract |
To evaluate the effect of adding bevacizumab to adjuvant paclitaxel and carboplatin and as maintenance on progression-free survival (PFS) in advanced or recurrent endometrial carcinoma (EMCA). |
| abstractGer |
To evaluate the effect of adding bevacizumab to adjuvant paclitaxel and carboplatin and as maintenance on progression-free survival (PFS) in advanced or recurrent endometrial carcinoma (EMCA). |
| abstract_unstemmed |
To evaluate the effect of adding bevacizumab to adjuvant paclitaxel and carboplatin and as maintenance on progression-free survival (PFS) in advanced or recurrent endometrial carcinoma (EMCA). |
| collection_details |
GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA |
| container_issue |
2 |
| title_short |
A phase II trial of paclitaxel, carboplatin, and bevacizumab in advanced and recurrent endometrial carcinoma (EMCA) |
| url |
https://doi.org/10.1016/j.ygyno.2014.12.004 |
| remote_bool |
true |
| author2 |
Drake, Richard Escobar, Pedro F. Nutter, Benjamin Rasool, Nabila Rose, Peter G. |
| author2Str |
Drake, Richard Escobar, Pedro F. Nutter, Benjamin Rasool, Nabila Rose, Peter G. |
| ppnlink |
ELV000708127 |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| author2_role |
oth oth oth oth oth |
| doi_str |
10.1016/j.ygyno.2014.12.004 |
| up_date |
2024-07-06T17:01:21.391Z |
| _version_ |
1803849859222994944 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV012713724</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230623101506.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180602s2015 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.ygyno.2014.12.004</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBVA2015001000028.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV012713724</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0090-8258(14)01559-5</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.11</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Simpkins, Fiona</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">A phase II trial of paclitaxel, carboplatin, and bevacizumab in advanced and recurrent endometrial carcinoma (EMCA)</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2015</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">6</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">To evaluate the effect of adding bevacizumab to adjuvant paclitaxel and carboplatin and as maintenance on progression-free survival (PFS) in advanced or recurrent endometrial carcinoma (EMCA).</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Drake, Richard</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Escobar, Pedro F.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Nutter, Benjamin</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Rasool, Nabila</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Rose, Peter G.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Academic Press</subfield><subfield code="a">Gibson, Diane M. ELSEVIER</subfield><subfield code="t">Frequency and predictors of missed visits to primary care and eye care providers for annually recommended diabetes preventive care services over a two-year period among U.S. adults with diabetes</subfield><subfield code="d">2017</subfield><subfield code="d">an international journal : official publication of the Society of Gynecologic Oncologists [u.a.]</subfield><subfield code="g">Orlando, Fla</subfield><subfield code="w">(DE-627)ELV000708127</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:136</subfield><subfield code="g">year:2015</subfield><subfield code="g">number:2</subfield><subfield code="g">pages:240-245</subfield><subfield code="g">extent:6</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.ygyno.2014.12.004</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.11</subfield><subfield code="j">Präventivmedizin</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">136</subfield><subfield code="j">2015</subfield><subfield code="e">2</subfield><subfield code="h">240-245</subfield><subfield code="g">6</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">610</subfield></datafield></record></collection>
|
| score |
7.4003296 |